Table 2.
Liver-related side effects after TARE reported in the largest series
| Study (year) | No of patients | Interval (days) post-treatment | Ascites (%) | Total bilirubin grade >3 (%) | Transaminases grade >3 (%) | Other liver-related SAEs |
|---|---|---|---|---|---|---|
| Lau et al57 (1998) | 71 | NR | NR | NR | 4% liver failure (not RILD) | |
| Dancey et al76 (2000) | 22 | NR | NR | 22a | 22a | Two potential treatment-related deaths |
| Geschwind et al77 (2004) | 80 | 0–90 | 7a | 16a | 6a | One treatment-related death |
| Carr et al55 (2004) | 65 | 0–180 | 12 | 38a | ||
| Salem et al59 (2005) | 43 | 0–90 | 7 | 14b | 5b | |
| Goin et al123 (2005) | 121 | 0–>90 | NR | NR | 5% treatment-related deaths | |
| Sangro et al126 (2006) | 24 | 0–90 | NR | 12b | Two treatment-related deaths | |
| Kulik et al111 (2008) | 82 (cirrhotic) | 0–180 | 18b | 40b | 4% encephalopathy CTC grade 3 | |
| 26 (non-cirrhotic) | 4b | 4b | 0% encephalopathy | |||
| Hilgard et al61 (2010) | 108 | 0–>90 | 0b | 23b | 0b | 3% encephalopathy CTC grade 3 |
| Kooby et al122 (2010) | 27 | 0–30 | NR | NR | 22% hepatic dysfunction | |
| Salem et al62 (2010) | 291 | 0–90 | NR | 14b | 20b | |
| Sangro et al10 (2011) | 325 | 0–90 | NR | 5b | 3b |
Notes:
a
CTC (>3 times the upper normal limit);90
b
SWOG (>200% increase from baseline). This Table was published in J Hepatol, 56(2), Sangro B, Iñarrairaegui M, Bilbao JI, Radioembolization for hepatocellular carcinoma, 464–473, © Copyright Elsevier 2012.25
Abbreviations: TARE, transarterial radioembolization; SAEs, serious adverse events; NR, not reported; RILD, radiation-induced liver disease; CTC, common terminology criteria; SWOG, Southwest Oncology Group.